Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
PMID: 34516245
2021
Antimicrobial agents and chemotherapy
Abstract: To study EFdA resistance patterns that may emerge in naive or tenofovir (TFV)-, emtricitabine/lamivudine (FTC/3TC)-, or zidovudine (AZT)-treated patients, we performed viral passaging experiments starting with WT, K65R, M184V, or D67N/K70R/T215F/K219Q HIV-1.
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.
Introduction: INSTI-naive highly treatment-experienced patients failing DTG cART have been found to have a virus with DRMs including G118R, D67N; H51H/Y, G118R, E138E/K, and less commonly R263R/K, V260I, R263R, N155H, G118R, and E138E.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Result: However, some minority DRMs at frequencies of 1%-5% disappeared, including N83D with PI-related, K70E, T215A, and K219E with NRTI-related and K101E, Y181C, H221Y and K238T with NNRTI-related, while others emerged, such as NNRTI-related V106A in patient GX088 at a frequency of 8.7%, and L23I, I47V and I84V with PI-related, D67N and
The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
Abstract: 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q
Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
PMID: 33654530
2020
The Pan African medical journal
Result: Predominant NNRTIs mutations were K103N, Y181C, G190A, H221Y, and K101E; NRTIs were M184V, Y115F, K65R, K70R, D67N and PIs were I54V, F53L and V82A (Table 2).
Table: D67N
Discussion: Our findings reveal major mutations conferring resistance to NRTIs with M184V, Y115F,
[Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile].
Abstract: The mutations in reverse transcriptase were M41L, L210W, D67N, K70E, M184V, K103N (6.36%, 95% CI 3.5-10.4), G190A, E138A, K101E, and I84V in protease.
Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
PMID: 31774913
2020
The Journal of infectious diseases
Method: Because some individuals may have been exposed to thymidine analogs before TDF-containing regimens, we excluded individuals with sequences containing TAMs:M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E.
Pretreatment HIV drug resistance spread within transmission clusters in Mexico City.
PMID: 31819984
2020
The Journal of antimicrobial chemotherapy
Result: Other frequently shared DRMs included: reverse transcriptase (RT) Y188L (11/175), RT T215S/C (24/175) and protease M46I (19/175), mostly at >=20% within-host frequency; and RT D67N/G/E (56/175) and RT P225H (16/175) as low-frequency variants.
Discussion: Here, sharing of specific DRMs at low within-host frequency (2%-19%), mainly RT D67N/G/E and P225H, between putative transmission pairs was observed relatively frequently (25 out of 66 clusters i
Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).
HIV mutation literature information.
PMID: 
2021
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT